David Silberg - Scopus Biopharma Advisor
Insider
David Silberg is Advisor of Scopus Biopharma
| Age | 74 |
| Phone | 212 479 2513 |
| Web | https://scopusbiopharma.com |
Scopus Biopharma Management Efficiency
The company has return on total asset (ROA) of (4.6089) % which means that it has lost $4.6089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.596) %, meaning that it created substantial loss on money invested by shareholders. Scopus Biopharma's management efficiency ratios could be used to measure how well Scopus Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jesse Shefferman | Protara Therapeutics | 53 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| CPA MS | Erasca Inc | 55 | |
| MBA MPH | Protara Therapeutics | 41 | |
| Andrew MBA | Monopar Therapeutics | 53 | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 41 | |
| Antony CPA | Forte Biosciences | 58 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Dominic Cundari | DiaMedica Therapeutics | 74 | |
| Hannah Fry | Protara Therapeutics | 34 | |
| Wei MD | Erasca Inc | 54 | |
| Jonathan MD | Erasca Inc | 53 | |
Management Performance
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 |
Scopus Biopharma Leadership Team
Elected by the shareholders, the Scopus Biopharma's board of directors comprises two types of representatives: Scopus Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scopus. The board's role is to monitor Scopus Biopharma's management team and ensure that shareholders' interests are well served. Scopus Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scopus Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ira Greenspan, Advisor Director | ||
| David Silberg, Advisor | ||
| Robert Gibson, S Chairman | ||
| Alan Horsager, PresofImmunoOncology BioTherapeutics |
Scopus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Scopus Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 21.09 M | ||||
| Shares Owned By Insiders | 50.66 % | ||||
| Shares Owned By Institutions | 2.15 % | ||||
| Number Of Shares Shorted | 23.77 K | ||||
| Price To Book | 2.42 X | ||||
| EBITDA | (26.18 M) | ||||
| Net Income | (26.95 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |